Novel Hydrogel: Targeted Delivery of Drugs for Rheumatoid Arthritis Patients
News Oct 12, 2017 | Original story from the Institute for Basic Research
IBS scientists developed a hydrogel made of polymeric acrylamide (blue spaghetti) linked with crosslinkers (black), which can accommodate drug molecules (purple stars) within its mesh (grey). In the presence of nitric oxide (red), the linker is cleaved and the drug molecules can be released. At the same time, the gel absorbs fluid from the surroundings and swells in size. Image credit: Park J. et al, Advanced Materials (2017)
IBS scientists at the Center for Self-Assembly and Complexity, within the Institute for Basic Science (IBS), invented a hydrogel to fight rheumatoid arthritis and other diseases. Published in Advanced Materials, this jelly-like material could be used to absorb extra fluids in swelling joints and release drugs.
Rheumatoid arthritis (RA) is a long-term disease that causes inflammation and deformity of the joints, and affects about 1% of the world population. In this autoimmune condition, the body's immune system attacks the soft tissue of the joints, leading to an accumulation of synovial fluid. While this clear fluid lubricates and nourishes the joints, its excess causes swelling and pain.
Immune cells at the inflamed joints are the predominant source of nitric oxide (NO), a gas with various physiological functions. “Nitric oxide is like a double-edge sword. It regulates inflammation and protects our body by killing external pathogens. However, when in excess, it is toxic and may cause RA, as well as other autoimmune diseases, cardiovascular diseases, and cancer,” explains the group leader, KIM Won Jong. Current RA treatments are based on anti-inflammatory drugs that relieve pain and inflammation, but IBS scientists tried a more challenging approach by targeting NO itself. NO is a transient gas, which stays in circulation for less than 10 seconds, before binding to other molecules.
The research team developed a gel responsive to such fugitive molecules, using acrylamide as a base material and a new crosslinker to keep it in place. Unlike the monomeric form, polymeric acrylamide hydrogel has little toxicity and can contain a large amount of water. In addition, the cross-linking agent (NOCCL) forms bridges between the acrylamide molecules creating a net, which can trap drug molecules inside. When NO cleaves the NOCCL bridges, the gel changes its structure, frees the drug and absorbs new liquid.
Although this is a preliminary study, the team confirmed that NOCCL crosslinking agent can selectively and sensitively react with NO. The scientists are now working on a nano-sized hydrogel in a RA mouse model. Moreover, these type of hydrogels could be useful for other diseases characterized by overexpression of NO, or maybe even as environmental sensors, since NO is also a polluting gas emitted in vehicle exhaust.
This article has been republished from materials provided by the Institute for Basic Research. Note: material may have been edited for length and content. For further information, please contact the cited source.
Park, J., Pramanick, S., Park, D., Yeo, J., Lee, J., Lee, H., & Kim, W. J. (2017). Therapeutic-Gas-Responsive Hydrogel. Advanced Materials. doi:10.1002/adma.201702859
Biomarker for Glioblastoma Predicts Clinical Course and Sensitivity to TreatmentNews
Scientists validate a biomarker indicative of patients with Glioblastoma prognosis and likely response to specific therapies.READ MORE
Biomedical Catalyst Award Goes To BioMoti, Pharmidex and Queen Mary University of LondonNews
The grant was awarded under the Biomedical Catalyst funding competition to support preclinical studies of new therapeutic approaches for hard-to-treat tumours including advanced ovarian, triple negative breast and pancreatic cancers.READ MORE
A New Tactic in the Fight Against Drug-Resistant InfectionsNews
$1 million research grant could lead to life-saving antibiotics.READ MORE